The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words-- including "health equity ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

MDVIP, the market leader in membership-based healthcare with a network of over 1,300 primary care physicians nationwide, has ...

Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...